Table 3. Summary of commercial cancer trial protocols and associated per patient TC differences: a negative TC represents a TC saving.
| Trial name or acronym | Cancer site and indication | NIHR portfolio (yes or no) | Trial phase | Experimental arm(s) | Local SOC | Duration of treatment | TC |
|---|---|---|---|---|---|---|---|
| A6181170 |
HCC Palliative |
Yes |
III Randomised |
Sunitinib |
Observation* |
48 weeks |
£0 |
| MISSION |
Lung Palliative |
Yes |
III Randomised |
Sorafenib |
Observation |
17 weeks |
£0 |
| Rad001 |
Renal Palliative |
No |
III Non-randomised |
Everolimus |
Best supportive care |
12 weeks |
£0 |
| SUMMIT-1 |
Melanoma Palliative |
Yes |
III Randomised |
Tasisulam |
Best supportive care* |
8 weeks |
£0 |
| Symmetry |
Melanoma Palliative |
No |
III Randomised |
STA-4783+paclitaxel |
Dacarbazine* |
2 weeks |
−£669 |
| SUCCEED |
Sarcoma Palliative |
No |
III Randomised |
AP23573 |
Observation |
18 weeks |
−£768 |
| Enthuse M1 |
Prostate Palliative |
No |
III Randomised |
ZD4054 |
Prednisolone |
15 weeks |
−£891 |
| IMA910-101 |
Colorectal Palliative |
No |
II Non-randomised |
Single low dose cyclophosphamide, IMA910+GCSF |
Observation |
32 weeks |
−£979 |
| COU-AA-302 |
Prostate Palliative |
No |
III Randomised |
Abiraterone+prednisolone |
Prednisolone |
46 weeks |
−£1073 |
| VDF111687 |
Renal Palliative |
No |
II Randomised |
Bevacizumab or pazopanib |
Everolimus* |
4 weeks |
−£3116 |
| BRIM 3 |
Melanoma Palliative |
No |
III Randomised |
Vemurafenib |
Dacarbazine |
10.5 weeks |
−£3119 |
| Study 6 NCRN063 |
Melanoma Palliative |
Yes |
II Randomised |
AZD6244 |
Dacarbazine |
24 weeks |
−£3930 |
| ATTRACT 2 |
Lung Palliative |
No |
III Randomised |
ASA404 and docetaxel |
Docetaxel |
18 weeks |
−£4285 |
| OncoVEX |
Melanoma Palliative |
Yes |
III Randomised |
OncoVEX |
Dacarbazine* |
24 weeks |
−£4455 |
| Affirm |
Prostate Palliative |
No |
III Randomised |
MDV3100 |
Mitoxantrone* |
18 weeks |
−£6445 |
| COU-AA-301 |
Prostate Palliative |
No |
III Randomised |
Abiraterone+prednisolone |
Mitoxantrone* |
23.5 weeks |
−£6557 |
| ATTRACT 1 |
Lung Palliative |
No |
III Randomised |
ASA404+carboplatin+paclitaxel |
Pemetrexed* Cisplatin |
10 weeks |
−£7112 |
| M10-440 |
Melanoma Palliative |
No |
II Randomised |
Veliparib 20 mg bd +TMZ, or Veliparib 40 mg bd+TMZ |
Dacarbazine* |
33 weeks |
−£8317 |
| Iceberg |
Gynae Palliative |
No |
II Randomised |
Olaparib 200 mg bd, or 400 mg bd |
Liposomal doxorubicin |
24 weeks |
−£10 244 |
| BIBF1199.26 |
Renal Palliative |
Yes |
II Randomised |
BIBF 1120 |
Sunitinib |
12 weeks |
−£11 268 |
| AVEO AV-951-09-299 |
Renal Palliative |
No |
III Randomised |
Tivozanib |
Sunitinib |
24 weeks |
−£13 515 |
| Torisel 404 |
Renal Palliative |
No |
III Randomised |
Temsirolimus |
Everolimus* |
21 weeks |
−£15 141 |
| COMPARZ |
Renal Palliative |
Yes |
III Randomised |
Pazopanib |
Sunitinib |
30 weeks |
−£17 005 |
| CAMN 107G 2301 |
GIST Palliative |
Yes |
III Randomised |
Nilotinib |
Imatinib |
13.5 months |
−£23 348 |
| AXIS |
Renal Palliative |
Yes |
III Randomised |
Axitinib |
Everolimus* |
10 weeks |
−£27 914 |
| Bevlin | Renal Palliative | No | II Non-randomised | Bevacizumab+IFN | Sunitinib | 33 months | −£71 480 |
Abbreviations: NIHR=National Institute for Health Research; SOC=standard of care; TC=treatment cost.
*
Local SOC differed from protocol standard comparator.